A Microfluidic System Coupling Amplified Nanofluidic Virion Purification and Mass Spectrometry for Detection of SARS-CoV-2
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20182021Known Financial Commitments (USD)
$334,234Funder
National Institutes of Health (NIH)Principal Investigator
AARON T TIMPERMANResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGNResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
A Microfluidic System Coupling Amplified Nanofluidic Virion Purification and Mass Spectrometry forDetection of SARS-CoV-2There is an urgent need for new methods and alternative techniques for viral detection in response to the SARS-CoV-2 pandemic. A novel strategy is proposed for viral detection that purifies the virions with ananofluidic/microfluidic (NF/MF) system prior to protein analysis by mass spectrometry. The NF/MF purificationsystem and protein analysis are highly complementary to and a radical departure from existing approaches. TheNF/MF system addresses the fundamental challenge of rapid and efficient purification of virions from the hugebackground of human cells and biomolecules. This novel approach will enable mining of the rich information thatis contained in the protein structures of the virus. In contrast with most other approaches, this technology will becapable of detecting mutated strains of SARS-CoV-2 and emergent viruses.The performance of the novel NF/MF will be fully characterized for different clinical needs. First, the extractionefficiency of the NF/MF system and the limits of detection for the complete diagnostic system will be measured.Second, application specific data acquisition and analysis strategies will be developed for the MS that are tunedto: 1) achieve the best detection limits for diagnostic testing, and 2) to gain the greatest percentage of the viralproteome for enhanced diagnostics for patients with high-viral loads.In addition to the gains in capabilities, it is expected that performance, costs, and sample throughput will befavorable. It is anticipated that limits of detection of 10 virions or better will be achieved with sample throughputof a few thousand samples per day per system. The simplicity of the process and ease of automation will reducepersonnel costs. Only a few consumables will be used that are orthogonal to the supply chain for RNA basedmethods. Thus, this technique is highly complementary to RNA-based approaches and would reducevulnerability to supply chain disruption. It is anticipated that these figures of merit and the potential applicationsfor utilizing the structural information contained in the proteins has the potential to revolutionize viral diagnosticsin both short-term and long-term.